natgillin/translations-raw huggingface dataset:
You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects'). 
• morate takoj povedati zdravniku, če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4 »Možni neželeni učinki«).
What Clopidogrel ratiopharm GmbH is and what it is used for What you need to know before you take Clopidogrel ratiopharm GmbH How to take Clopidogrel ratiopharm GmbH Possible side effects 
Kaj je zdravilo Klopidogrel ratiopharm GmbH in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel ratiopharm GmbH Kako jemati zdravilo Klopidogrel ratiopharm GmbH
• Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
• odraslih bolnikih z akutnim koronarnim sindromom: akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
Clopidogrel ratiopharm GmbH contains hydrogenated castor oil which may cause stomach upset and diarrhoea. 
Klopidogrel ratiopharm GmbH vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking clopidogrel 75 mg/day. 
Odmerek 0,2 mg/kg je dosegel povprečno 49,3 % zavrtje (agregacija trombocitov povzročena s 5 µM ADP), primerljivo kot pri odraslih ob uporabi zdravila klopidogrela v odmerku 75 mg/dan.
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints o heparin or any other injectable medicine used to reduce blood clotting o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach - fluconazole or voriconazole medicines to treat fungal infections 
Še posebej pomembno je, da obvestite svojega zdravnika, če jemljete - zdravila, ki lahko povečajo tveganje za krvavitve, kot so: o peroralni antikoagulanti, zdravila, ki preprečujejo nastanek krvnih strdkov, o nesteroidna protivnetna zdravila, ki se običajno uporabljajo za lajšanje bolečine in/ali vnetja mišic ali sklepov, o heparin, ali katero koli drugo zdravilo v obliki injekcij, ki se uporablja za zmanjševanje strjevanja krvi, o tiklopidin, druga antiagregacijska zdravila, o selektivni zaviralci privzema serotonina (na primer fluoksetin ali fluvoksamin, a ne le tadva), zdravila, ki se običajno uporabljajo za zdravljenje depresije,
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel. 
Podatki študije CAPRIE kažejo, da se lahko fenitoin in tolbutamid, ki se presnavljata s CYP2C9,
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
- če je zamuda manj kot 12 ur po pravem času: bolnik naj odmerek vzame takoj, potem pa naslednji odmerek ob pravem času.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel ratiopharm GmbH (4 tablets of 75 mg) once at the start of treatment. 
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja da 300 mg zdravila Klopidogrel ratiopharm GmbH v enkratnem odmerku (štiri 75mg tablete).
If you have any further questions, ask your doctor or your pharmacist. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
Zlasti post hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčno žilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
EU/1/09/541/001 - Cartons of 14 film-coated tablets in Alu/Alu blisters EU/1/09/541/002 - Cartons of 28 film-coated tablets in Alu/Alu blisters EU/1/09/541/003 - Cartons of 30 film-coated tablets in Alu/Alu blisters EU/1/09/541/004 - Cartons of 50 film-coated tablets in Alu/Alu blisters EU/1/09/541/005 - Cartons of 84 film-coated tablets in Alu/Alu blisters EU/1/09/541/006 - Cartons of 90 film-coated tablets in Alu/Alu blisters EU/1/09/541/007 - Cartons of 100 film-coated tablets in Alu/Alu blisters EU/1/09/541/008 - Cartons of 7 film-coated tablets in Alu/Alu blisters 
EU/1/09/541/002- škatle s 14 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/09/541/004 - škatle z 28 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/09/541/006 - škatle s 30 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/09/541/009 - škatle s 50x1 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/09/541/010 - škatle z 84 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/09/541/012 - škatle z 90 filmsko obloženimi tabletami v aluminijastih pretisnih omotih EU/1/09/541/014 - škatle s 100 filmsko obloženimi tabletam v aluminijastih pretisnih omotih EU/1/09/541/019 - škatle s 7 filmsko obloženimi tabletami v aluminijastih pretisnih omotih
What you need to know before you take Clopidogrel ratiopharm GmbH Do not take Clopidogrel ratiopharm GmbH 
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel ratiopharm GmbH Ne jemljite zdravila Klopidogrel ratiopharm GmbH:
If you experience prolonged bleeding when taking Clopidogrel ratiopharm GmbH. 
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel ratiopharm GmbH.
What Clopidogrel ratiopharm GmbH is and what it is used for 
Kaj je zdravilo Klopidogrel ratiopharm GmbH in za kaj ga uporabljamo
STATEMENT OF ACTIVE SUBSTANCE(S) 
Pomožna(e) snov(i)
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets are white to off-white, marbled, round and biconvex. 
Zdravilo Klopidogrel ratiopharm GmbH 75 mg tablete so bele do belkaste, marmorirane, okrogle in bikonveksne filmsko obložene tablete.
Cellulose, microcrystalline (E460) Crospovidone type A Castor oil, hydrogenated 
jedro tablete: makrogol 6000 mikrokristalna celuloza (E460) krospovidon (vrsta A) hidrogenirano ricinusovo olje filmska obloga:
-Rare side effect (may affect up to 1 in 1,000 people): Vertigo, enlarged breasts in males. 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): vrtoglavica, povečanje prsi pri moških.
Clopidogrel ratiopharm GmbH contains the active ingredient Clopidogrel which belongs to a group of medicines called antiplatelet medicinal products. 
Zdravilo Klopidogrel ratiopharm GmbH vsebuje zdravilno učinkovino klopidogrel, ki spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel ratiopharm GmbH in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Klopidogrel ratiopharm GmbH v kombinaciji z acetilsalicilno kislino, učinkovino,
Clopidogrel ratiopharm GmbH contains hydrogenated castor oil 
Zdravilo Klopidogrel ratiopharm GmbH vsebuje hidrogenirano ricinusovo olje
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers. 
povprečno IPA (5 µM ADP) je bilo 24 % (24 ur) in 37 % (5. dan) v primerjavi z 39 % (24 ur) in 58 %
If you take more Clopidogrel ratiopharm GmbH than you should 
Če ste vzeli večji odmerek zdravila Klopidogrel ratiopharm GmbH, kot bi smeli
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions. 
Vendar pa so bolniki, ki so bili vključeni v klinično preskušanje klopidogrela, prejemali sočasno različna zdravila, vključno z diuretiki, zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACEI), kalcijevimi antagonisti, učinkovinami za zniževanje holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z insulinom),
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous, or exfoliative, urticaria, eczema, lichen planus 
(sindrom DIHS, DrugInduced Hypersensitivity Syndrome), kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS, Drug Rash with Eosinophilia and Systemic Symptoms), eritematozen ali eksfoliativen izpuščaj, urtikarija, ekcem, lihen planus
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia 
(hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis,
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tél/Tel: +49 731 402 02 
Allemagne/Deutschland ratiopharm GmbH Tél/Tel: +49 731 402 02
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4). 
Terapevtske izkušnje pri bolnikih z okvaro ledvic so omejene (glejte poglavje 4.4).
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
104 tedne v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat višjo izpostavljenost kot pri človeku ob prejemanju kliničnega odmerka 75 mg/dan).
- efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections, 
- flukonazol ali vorikonazol, zdravila za zdravljenje glivičnih okužb,
Contents of the pack and other information What Clopidogrel ratiopharm GmbH contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Klopidogrel ratiopharm GmbH
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2 - 2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing. 
2,2-2,5 ng/ml po enem 75-mg peroralnem odmerku) se je pojavila približno 45 minut po odmerjanju.
How to store Clopidogrel ratiopharm GmbH Contents of the pack and other information 
Shranjevanje zdravila Klopidogrel ratiopharm GmbH Vsebina pakiranja in dodatne informacije
Clopidogrel ratiopharm GmbH with food and drink 
Zdravilo Klopidogrel ratiopharm GmbH skupaj s hrano in pijačo
You have been prescribed Clopidogrel ratiopharm GmbH to help prevent blood clots and reduce the risk of these severe events because: 
Zdravilo Klopidogrel ratiopharm GmbH vam je predpisano za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate stanje otrdelih arterij (znano tudi kot ateroskleroza), in
-Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn. 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): driska, bolečina v trebuhu, slaba prebava ali zgaga.
43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01). 
30 bolnikih (9,3 %) v skupini z deeskaliranim DAPT in pri 76 bolnikih (23,5 %) v skupini z nespremenjenim DAPT (p < 0,01).
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg na dan, n=1.752) ali placebo (n=1.739), oboje v kombinaciji z ASA (150 mg do 325 mg kot udarni odmerek, nato 75 mg do 162 mg na dan),
Other medicines and Clopidogrel ratiopharm GmbH 
Druga zdravila in zdravilo Klopidogrel ratiopharm GmbH
You have a condition of hardening of arteries (also known as atherosclerosis), and You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease (disturbed blood flow in arms or legs caused by vascular occlusions) or 
- ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (moten krvni pretok v rokah ali nogah, ki ga povzroči zapora žil) ali - ste doživeli hudo obliko bolečine v prsih, znano kot “nestabilna angina” ali “miokardni infarkt” (srčni napad).
signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions'). 
To so lahko znaki redkega zmanjšanja števila določenih krvnih celic, - znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo
Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1309), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1309), in combination with ASA (<100 mg/day). 
(od 0. do 14. dne) (n = 1309) bodisi na prejemanje prasugrela 5 ali 10 mg/dan (od 0. do 7. dne) s poznejšim deeskaliranjem na 75 mg klopidogrela na dan (od 8. do 14. dne) (n = 1309) v kombinaciji z ASA (< 100 mg/dan).
(alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. 
Bolniki morajo biti obveščeni, da je lahko čas, potreben za zaustavitev krvavitve, daljši kot ponavadi, ko jemljejo klopidogrel (sam ali v kombinaciji z ASA) in da morajo poročati svojemu zdravniku o kakršni koli neobičajni krvavitvi (mesto ali trajanje).
If you forget to take Clopidogrel ratiopharm GmbH 
Če ste pozabili vzeti zdravilo Klopidogrel ratiopharm GmbH
While you are taking Clopidogrel ratiopharm GmbH: 
Ko jemljete zdravilo Klopidogrel ratiopharm GmbH:
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5). 
heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs) vključno z zaviralci COX-2, ali s selektivnimi zaviralci privzema serotonina (SSRI) ali z drugimi zdravili, ki so povezana s tveganjem za krvavitve, kot je pentoksifilin (glejte poglavje 4.5).
What Clopidogrel ratiopharm GmbH looks like and contents of the pack 
Izgled zdravila Klopidogrel ratiopharm GmbH in vsebina pakiranja
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG). 
Delež bolnikov s primarnim opazovanim dogodkom [srčno-žilna (SŽ) smrt, miokardni infarkt (MI) ali kap] je bil 582 (9,3 %) v skupini, zdravljeni s klopidogrelom, in 719 (11,4 %) v skupini, ki je prejemala placebo, to je 20 % zmanjšanje relativnega tveganja (95 % IZ od 10 % - 28 %; p=0,00009)
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects'). 
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets 
Klopidogrel ratiopharm GmbH 75 mg filmsko obložene tablete
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel 
Klopidogrel ratiopharm GmbH 75 mg filmsko obložene tablete klopidogrel
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel ratiopharm GmbH. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta,
How to take Clopidogrel ratiopharm GmbH 
Kako jemati zdravilo Klopidogrel ratiopharm GmbH
Vascular disorders 
Bulozen dermatitis
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy. 
bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
Package leaflet: Information for the user Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel 
Navodilo za uporabo Klopidogrel ratiopharm GmbH 75 mg filmsko obložene tablete klopidogrel
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block). 
24 urah po nastopu simptomov, ki bi lahko kazali na miokardni infarkt, z neustreznimi vrednostmi EKG, ki so to potrjevale (elevacija ST spojnice, depresija ST spojnice ali levokračni blok).
How to store Clopidogrel ratiopharm GmbH 
Shranjevanje zdravila Klopidogrel ratiopharm GmbH
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia 
bolečine v trebuhu, dispepsija
Clopidogrel is extensively metabolised by the liver. 
Biotransformacija Klopidogrel se v jetrih izdatno presnovi.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 28 July 2009 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
(očistek kreatinina 5 do 15 ml/min) inhibicija z ADP sprožene agregacije trombocitov manjša (25 %)
Date of first authorisation: 13 April 1999 Date of latest renewal: 25 March 2009 
Datum prve odobritve: 13.04.1999 Datum zadnjega podaljšanja: 25.03.2009
EXP For single use only. 
EXP Samo za enkratno uporabo.
The changes observed at the low dose of the 13-week studies can be classified as minimal and fully reversible. 
Spremembe, ki so jih zasledili po dajanju majhnih odmerkov v 13-tedenskih raziskavah, lahko opredelimo kot minimalne in popolnoma reverzibilne.
Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 
zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do
This can be clarified by an arteriogram. 
To lahko odkrijemo z arteriografijo.
However, the treatment is specifically a loco-regional treatment and is not expected to influence survival. 
Toda zdravljenje je specifično lokalnoregionalno in ne vpliva na preživetje.
In particular, you should tell your doctor if you are using medicines to lower blood pressure (to treat hypertension). 
Zdravniku še zlasti povejte, če jemljete zdravila za znižanje krvnega tlaka (za zdravljenje hipertenzije).
The formulation does not contain a preservative and is for single use only. 
Pripravek ne vsebuje konzervansa in je namenjen samo za enkratno uporabo.
Induction of general anaesthesia and subsequent mechanical ventilation should be applied according to standard methods. 
Indukcijo splošne anestezije in sledečo mehanično ventilacijo je treba izvajati po standardni metodi.
Systemic adverse reactions include mild constitutional reactions and toxic effects on different organ systems. 
Sistemski neželeni učinki vključujejo blage konstitucionalne reakcije in toksične učinke na različne organske sisteme.
If you do, this will not be until at least six weeks after your first ILP. 
Če ga bodo, to ne bo prej kot najmanj šest tednov po prvi perfuziji.
- if you are allergic to tasonermin or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na tasonermin ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
There are no adequate data from the use of tasonermin in pregnant women. 
Ni zadostnih podatkov o uporabi tasonermina pri nosečnicah.
Reconstituted solution Chemical and physical in-use stability has been demonstrated for up to 48 hours at 25°C. 
Dokazana je bila 48-urna kemična in fizikalna stabilnost med uporabo pri 25 °C.
Treatment with anti-TNFα antibodies is not recommended. 
Dajanja protiteles anti-TNFα ne priporočamo.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
This technique ensures that Beromun is kept within the affected arm or leg. 
Ta tehnika zagotavlja, da zdravilo Beromun ostane znotraj prizadete roke ali noge.
The temperature should then be increased to >39°C (but not exceeding 40°C) in two different sites of measurement in the tumour area. 
Nato temperaturo povečamo do > 39 °C (toda ne na več kot 40 °C) na dveh različnih merilnih mestih v predelu tumorja.
The safety and efficacy of Beromun in children under 18 years have not been established. 
Pediatrična populacija Varnost in učinkovitost zdravila Beromun pri otrocih, mlajših od 18 let, še nista bili dokazani.